Hepatocyte growth factor as inducer of gefitinib resistance in non-small cell lung cancer harboring EGFR activating mutations

被引：0
|
作者：
Yano, S.
Wang, W.
Li, Q.
Yamada, T.
Matsumoto, K.
Mitsudomi, T.
Yatabe, Y.
Hanibuchi, M.
Nishioka, Y.
Sone, S.
机构：
[1] Kanazawa Univ, Canc Res Inst, Kanazawa, Ishikawa 920, Japan
[2] Aichi Canc Ctr, Nagoya, Aichi 464, Japan
[3] Univ Tokushima, Grad Sch, Tokushima 770, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19034
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [31] Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells
    Chen, Xi
    Zhou, Jian-Ya
    Zhao, Jing
    Chen, Jun-Jun
    Ma, Shan-Ni
    Zhou, Jian-Ying
    ANTI-CANCER DRUGS, 2013, 24 (10) : 1039 - 1046
  • [32] Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor
    Okamoto, Isamu
    Takahashi, Toshiaki
    Okamoto, Hiroaki
    Nakagawa, Kazuhiko
    Watanabe, Koshiro
    Nakamatsu, Kiyoshi
    Nishimura, Yasumasa
    Fukuoka, Masahiro
    Yamamoto, Nobuyuki
    LUNG CANCER, 2011, 72 (02) : 199 - 204
  • [33] Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese
    Uramoto, H
    Sugio, K
    Oyama, T
    Ono, K
    Sugaya, M
    Yoshimatsu, T
    Hanagiri, T
    Morita, M
    Yasumoto, K
    LUNG CANCER, 2006, 51 (01) : 71 - 77
  • [34] Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor-Activating Mutations
    Yano, Seiji
    Wang, Wei
    Li, Qi
    Matsumoto, Kunio
    Sakurama, Haruko
    Nakamura, Takahiro
    Ogino, Hirokazu
    Kakiuchi, Soji
    Hanibuchi, Masaki
    Nishioka, Yasuhiko
    Uehara, Hisanori
    Mitsudomi, Tetsuya
    Yatabe, Yasushi
    Nakamura, Toshikazu
    Sone, Saburo
    CANCER RESEARCH, 2008, 68 (22) : 9479 - 9487
  • [35] Low-Dose Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer Harboring Sensitive Epidermal Growth Factor Receptor Mutations
    Satoh, Hironori
    Inoue, Akira
    Kobayashi, Kunihiko
    Maemondo, Makoto
    Oizumi, Satoshi
    Isobe, Hiroshi
    Gemma, Akihiko
    Saijo, Yasuo
    Yoshizawa, Hirohisa
    Hagiwara, Koichi
    Nukiwa, Toshihiro
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (08) : 1413 - 1417
  • [36] Effectiveness Of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors On Non-Small Cell Lung Cancer Harboring Rare EGFR Mutations
    Chang, L. -C.
    Chen, K. -Y.
    Shih, J. -Y.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [37] Mutations of the epidermal growth factor receptor (EGFR) gene in non-small cell lung cancer (NSCLC).
    Sonobe, M
    Katakura, H
    Adachi, T
    Wada, H
    Tanaka, F
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 637S - 637S
  • [38] Anlotinib with gefitinib as first-line therapy in advanced non-small cell lung cancer harboring EGFR mutations: A phase II study
    Ji, Y.
    Wang, X.
    Lou, Z.
    ANNALS OF ONCOLOGY, 2021, 32 : S979 - S979
  • [39] EGFR mutations and gefitinib sensitivity in patients with metastatic non-squamous non-small cell lung cancer
    Moiseyenko, V.
    Imyanitov, E.
    Levchenko, E.
    Procenko, S.
    Orlova, R.
    Iyevleva, A.
    Buslov, K.
    Ulibina, Y.
    Matsko, D.
    Moiseyenko, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [40] First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations
    Tomohito Kuwako
    Hisao Imai
    Tomomi Masuda
    Yosuke Miura
    Kaori Seki
    Reiko Yoshino
    Kyoichi Kaira
    Mitsuyoshi Utsugi
    Kimihiro Shimizu
    Noriaki Sunaga
    Yoshio Tomizawa
    Shinichi Ishihara
    Takao Ishizuka
    Akira Mogi
    Takeshi Hisada
    Koichi Minato
    Atsushi Takise
    Ryusei Saito
    Masanobu Yamada
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 761 - 769
12345